Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal

Trends Endocrinol Metab. 2023 Jan;34(1):49-60. doi: 10.1016/j.tem.2022.11.004. Epub 2022 Nov 26.

Abstract

Diabetes is associated with vascular injury and the onset of macrovascular complications. Advanced glycation endproducts (AGEs) and the AGE precursor methylglyoxal (MGO) have been identified as key players in establishing the relationship between diabetes and vascular injury. While most research has focused on the link between AGEs and vascular injury, less is known about the effects of MGO on vasculature. In this review, we focus on the mechanisms linking AGEs and MGO to the development of atherosclerosis. AGEs and MGO are involved in many stages of atherosclerosis progression. However, more research is needed to determine the exact mechanisms underlying these effects. Nevertheless, AGEs and MGO could represent valid therapeutic targets for the macrovascular complications of diabetes.

Keywords: Advanced glycation endproducts; atherosclerosis; diabetes; macrovascular complications; methylglyoxal.

Publication types

  • Review

MeSH terms

  • Atherosclerosis*
  • Diabetes Mellitus*
  • Glycation End Products, Advanced
  • Humans
  • Magnesium Oxide
  • Pyruvaldehyde
  • Vascular System Injuries*

Substances

  • Glycation End Products, Advanced
  • Pyruvaldehyde
  • Magnesium Oxide